• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oral drug delivery startup raises $39m for robotic pill

September 13, 2017 By Sarah Faulkner

Rani TherapeuticsSan Jose, Calif.-based Rani Therapeutics has some seriously big-name backers: Alphabet (NSDQ:GOOGL), Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN) have all invested in the startup. This month, the company raised $38.7 million as part of a $126.5 million offering of equity and options or warrants, according to an SEC filing.

So far, 12 investors have contributed to the offering. Rani Therapeutics also said that it plans to set aside some of the money for sales commissions.

The company’s technology looks to provide an alternative to needle-based injections as a drug-delivery route. Rani has created a robotic pill that travels through the stomach and eventually reaches the intestine, where the device injects the drug directly into the intestinal wall.

The needles will later dissolve naturally after injecting the drug, according to the company.

The device has yet to be used with patients, as the company is still in its preclinical stage. But Rani plans to apply its technology to convert injectable drugs, like insulin, into oral pills.

In mid-2015, the company inked a collaboration with Novartis to evaluate Rani’s oral biotherapeutics drug delivery platform.

Last year, Rani announced a partnership with MedImmune, AstraZeneca’s global biologics R&D arm, to assess the company’s technology for use in the metabolic disease field.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: alphabet, AstraZeneca plc, Novartis, ranitherapeutics

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS